Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Reddy, Teegala Lakshminarayan ^a,b   Garikapati, Koteswara Rao ^a,b   Reddy, S Gopal ^a   Reddy, B V Subba ^a   Yadav, J S ^a   Bhadra, Utpal ^c   Bhadra, Manika Pal ^a,b  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

^c CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1,2-DISTEAROYLPHOSPHATIDYLETHANOLAMINE; ANTINEOPLASTIC AGENT; BCL2 PROTEIN, HUMAN; DIOLEOYL PHOSPHATIDYLETHANOLAMINE; IMIDAZOLE; IMIDAZOLE DERIVATIVE; KOJIC ACID; LIPOSOME; NANOPARTICLE; PACLITAXEL; PHOSPHATIDYLETHANOLAMINE; PROTEIN BCL 2; PYRONE DERIVATIVE; SMALL INTERFERING RNA;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG FORMULATION; EXPERIMENTAL MELANOMA; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; PATHOLOGY; PH; SKIN TUMOR; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HYDROGEN-ION CONCENTRATION; IMIDAZOLES; LIPOSOMES; MELANOMA, EXPERIMENTAL; MICE; NANOPARTICLES; PACLITAXEL; PHOSPHATIDYLETHANOLAMINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRONES; RNA, SMALL INTERFERING; SKIN NEOPLASMS; TUMOR BURDEN;

EID: 84994056583     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep35223     Document Type: Article

References (43)

1. Trussardi, A. et al. Sequential overexpression of LRP and MRP but not P-gp 170 in VP16-selected A549 adenocarcinoma cells. Int J Oncol 13, 543-548 (1998).
2. Berger, W. et al. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in nonsmall cell lung cancer: prognostic implications. J Cancer Res Clin Oncol 131, 355-363, doi: 10.1007/s00432-004-0653-9 (2005).
3. Chowdhury, S., Burbridge, S. & Harper, P. G. Chemotherapy for the treatment of hormone-refractory prostate cancer. Int J Clin Pract 61, 2064-2070, doi: 10.1111/j.1742-1241.2007.01551.x (2007).
4. Sun, T. M. et al. Simultaneous Delivery of siRNA and Paclitaxel via a "Two-in-One" Micelleplex Promotes Synergistic Tumor Suppression. Acs Nano 5, 1483-1494, doi: 10.1021/nn103349h (2011).
5. Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G. & Sood, A. K. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11, 59-67, doi: 10.1038/nrc2966 (2011).
6. Sun, Y. et al. Synthesis and characterization of pH-sensitive poly(itaconic acid)-poly(ethylene glycol)-folate-poly(l-histidine) micelles for enhancing tumor therapy and tunable drug release. Journal of colloid and interface science 458, 119-129, doi: 10.1016/j. jcis.2015.07.008 (2015).
7. Yang, X. et al. Multifunctional stable and pH-responsive polymer vesicles formed by heterofunctional triblock copolymer for targeted anticancer drug delivery and ultrasensitive MR imaging. ACS Nano 4, 6805-6817, doi: 10.1021/nn101670k (2010).
8. Zhou, Z. et al. Molecularly precise dendrimer-drug conjugates with tunable drug release for cancer therapy. Angew Chem Int Ed Engl 53, 10949-10955, doi: 10.1002/anie.201406442 (2014).
9. Reddy, T. L. et al. Para amino benzoic acid-derived self-assembled biocompatible nanoparticles for efficient delivery of siRNA. Int J Nanomedicine 10, 6411-6423, doi: 10.2147/IJN.S86238 (2015).
10. Yin, T. et al. Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes. Biomaterials 35, 5932-5943, doi: 10.1016/j.biomaterials.2014.03.072 (2014).
11. Park, C., Lee, K. & Kim, C. Photoresponsive cyclodextrin-covered nanocontainers and their sol-gel transition induced by molecular recognition. Angew Chem Int Ed Engl 48, 1275-1278, doi: 10.1002/anie.200803880 (2009).
12. Qiu, Y. & Park, K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev 53, 321-339 (2001).
13. Liu, R., Zhao, X., Wu, T. & Feng, P. Tunable redox-responsive hybrid nanogated ensembles. J Am Chem Soc 130, 14418-14419, doi: 10.1021/ja8060886 (2008).
14. Su, J., Chen, F., Cryns, V. L. & Messersmith, P. B. Catechol polymers for pH-responsive, targeted drug delivery to cancer cells. Journal of the American Chemical Society 133, 11850-11853, doi: 10.1021/ja203077x (2011).
15. Moku, G., Gulla, S. K., Nimmu, N. V., Khalid, S. & Chaudhuri, A. Delivering anti-cancer drugs with endosomal pH-sensitive anticancer liposomes. Biomater Sci, doi: 10.1039/c5bm00479a (2016).
16. Gerweck, L. E. Tumor pH: implications for treatment and novel drug design. Seminars in radiation oncology 8, 176-182 (1998).
17. Moitra, P., Kumar, K., Kondaiah, P. & Bhattacharya, S. Efficacious anticancer drug delivery mediated by a pH-sensitive self-assembly of a conserved tripeptide derived from tyrosine kinase NGF receptor. Angew Chem Int Ed Engl 53, 1113-1117, doi: 10.1002/anie.201307247 (2014).
18. Lee, Y. et al. Efficient delivery of bioactive antibodies into the cytoplasm of living cells by charge-conversional polyion complex micelles. Angew Chem Int Ed Engl 49, 2552-2555, doi: 10.1002/anie.200905264 (2010).
19. Sung, H. W., Sonaje, K., Liao, Z. X., Hsu, L. W. & Chuang, E. Y. pH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: from mechanism to therapeutic applications. Acc Chem Res 45, 619-629, doi: 10.1021/ar200234q (2012).
20. Griset, A. P. et al. Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system. J Am Chem Soc 131, 2469-2471, doi: 10.1021/ja807416t (2009).
21. Collins, D., Litzinger, D. C. & Huang, L. Structural and functional comparisons of pH-sensitive liposomes composed of phosphatidylethanolamine and three different diacylsuccinylglycerols. Biochimica et biophysica acta 1025, 234-242 (1990).
22. Malamas, A. S., Gujrati, M., Kummitha, C. M., Xu, R. & Lu, Z. R. Design and evaluation of new pH-sensitive amphiphilic cationic lipids for siRNA delivery. J Control Release 171, 296-307, doi: 10.1016/j.jconrel.2013.06.019 (2013).
23. Obata, Y., Tajima, S. & Takeoka, S. Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo. J Control Release 142, 267-276, doi: 10.1016/j.jconrel.2009.10.023 (2010).
24. Garu, A. et al. Examples of Tumor Growth Inhibition Properties of Liposomal Formulations of pH-Sensitive Histidinylated Cationic Amphiphiles. ACS Biomaterials Science & Engineering 1, 646-655 (2015).
25. Lajis, A. F. B., Hamid, M. & Ariff, A. B. Depigmenting Effect of Kojic Acid Esters in Hyperpigmented B16F1 Melanoma Cells. J Biomed Biotechnol, doi: Artn 95245210.1155/2012/952452 (2012).
26. Pramanik, D. et al. Lipopeptide with a RGDK tetrapeptide sequence can selectively target genes to proangiogenic alpha5beta1 integrin receptor and mouse tumor vasculature. Journal of medicinal chemistry 51, 7298-7302, doi: 10.1021/jm800915y (2008).
27. Tagalakis, A. D., He, L., Saraiva, L., Gustafsson, K. T. & Hart, S. L. Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery. Biomaterials 32, 6302-6315, doi: 10.1016/j.biomaterials.2011.05.022 (2011).
28. Cory, S. & Adams, J. M. Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer cell 8, 5-6, doi: 10.1016/j.ccr.2005.06.012 (2005).
29. Guo, X. L. et al. Targeting autophagy potentiates chemotherapy-induced apoptosis and proliferation inhibition in hepatocarcinoma cells. Cancer letters 320, 171-179, doi: 10.1016/j.canlet.2012.03.002 (2012).
30. Geschwind, J. F., Ko, Y. H., Torbenson, M. S., Magee, C. & Pedersen, P. L. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer research 62, 3909-3913 (2002).
31. Wang, J., Zhang, Z., Wang, X., Wu, W. & Jiang, X. Size-and pathotropism-driven targeting and washout-resistant effects of boronic acid-rich protein nanoparticles for liver cancer regression. Journal of controlled release: official journal of the Controlled Release Society 168, 1-9, doi: 10.1016/j.jconrel.2013.02.019 (2013).
32. Prabhakar, U. et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer research 73, 2412-2417, doi: 10.1158/0008-5472.CAN-12-4561 (2013).
33. Shi, L., Tang, C. & Yin, C. Glycyrrhizin-modified O-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma. Biomaterials 33, 7594-7604, doi: 10.1016/j.biomaterials.2012.06.072 (2012).
34. Zhang, Q., Ko, N. R. & Oh, J. K. Recent advances in stimuli-responsive degradable block copolymer micelles: synthesis and controlled drug delivery applications. Chemical communications 48, 7542-7552, doi: 10.1039/c2cc32408c (2012).
35. Fomina, N., Sankaranarayanan, J. & Almutairi, A. Photochemical mechanisms of light-triggered release from nanocarriers. Advanced drug delivery reviews 64, 1005-1020, doi: 10.1016/j.addr.2012.02.006 (2012).
36. Gao, J. et al. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA. Biomaterials 34, 10084-10098, doi: 10.1016/j.biomaterials.2013.08.088 (2013).
37. Wiradharma, N., Tong, Y. W. & Yang, Y. Y. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect. Biomaterials 30, 3100-3109, doi: 10.1016/j.biomaterials.2009.03.006 (2009).
38. Budker, V., Gurevich, V., Hagstrom, J. E., Bortzov, F. & Wolff, J. A. pH-sensitive, cationic liposomes: a new synthetic virus-like vector. Nature biotechnology 14, 760-764, doi: 10.1038/nbt0696-760 (1996).
39. Yan, F. et al. Therapeutic ultrasonic microbubbles carrying paclitaxel and LyP-1 peptide: preparation, characterization and application to ultrasound-assisted chemotherapy in breast cancer cells. Ultrasound in medicine & biology 37, 768-779, doi: 10.1016/j. ultrasmedbio.2011.02.006 (2011).
40. Wang, C., Guo, L. B., Ma, J. Y., Li, Y. M. & Liu, H. M. Establishment and characterization of a paclitaxelresistant human esophageal carcinoma cell line. International journal of oncology 43, 1607-1617, doi: 10.3892/ijo.2013.2083 (2013).
41. Bae, K. H., Lee, J. Y., Lee, S. H., Park, T. G. & Nam, Y. S. Optically traceable solid lipid nanoparticles loaded with siRNA and paclitaxel for synergistic chemotherapy with in situ imaging. Advanced healthcare materials 2, 576-584, doi: 10.1002/adhm.201200338 (2013).
42. Qu, M. H. et al. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer. International journal of pharmaceutics 474, 112-122, doi: 10.1016/j.ijpharm.2014.08.019 (2014).
43. Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010).